Trump Better Off in Congress Than Court for Drug Ad Price Fight

The Trump administration would be better off taking a fight over drug pricing transparency to Congress rather than to court, according to lawyers watching the case.

The government would face a significant challenge if it did appeal a federal judge’s July 8 decision to strike down a rule that would have required drug companies to disclose their list prices in TV advertising, said Deborah Shelton, a partner at Arent Fox LLP in Washington.

“Perhaps the better approach is directed at other more meaningful efforts, including legislative, that may help to further fuel competition,” she said.

Merck & Co., Eli Lilly ...